Translating Emerging Antigen Specific Immune Tolerance Approaches for Therapeutic Applications

Accelerate the progression of ethical and effective antigen specific immunotherapies through the clinic, optimize the discovery of novel targets and explore novel therapeutic approaches harnessing combination therapies.

The 4th Antigen Specific Immune Tolerance Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

Here are highlights from the 3rd Antigen Specific Immune Tolerance Summit:

  • World-class speaking faculty made up of 26 industry representatives including Novo Nordisk, Pfizer, Merck, Eli Lilly, ITN & FDA
  • Cross-learning opportunities from parallel fields tackling immune tolerance and better understand the fundamental mechanisms that lie behind tolerance induction
  • A learning journey across three conference days, tackling all elements of drug development from discovery to clinical development
  • Practical insight from those describing recent clinical trials and determine what mechanisms lie behind successful and unsuccessful clinical trials
  • Novel therapeutics in combination with antigen-specific immunotherapies and drive the progression of drug development towards the clinic
  • Intimate networking opportunities with key opinion leaders from large pharma, biotech and academia through discursive and engaging platforms that spark conversation and debate

“This meeting will provide opportunities to network with key scientists, hear about the latest developments and state-of-the-art science in the field of immune tolerance”

Antoon Van Oosterhout
VP & Head Allergic Inflammation Discovery Performance Unit

“I look forward to participating at this summit as cross-disease and cross-discipline exchanges are critical if we are to make disease- modifying therapy a reality in type 1 diabetes”

Carla Greenbaum
Director- Diabetes Program
Benaroya Research Institute